The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Items 301–400 of 1,000
Prospects of charged cyclodextrins in biomedical applications
Sehgal, V., Pandey, S. P., & Singh, P. K. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121348 · Cited by 46
Davodabadi, F., Mirinejad, S., Malik, S., Dhasmana, A., Ulucan‐Karnak, F., Sargazi, S., Sargazi, S., Fathi‐karkan, S., & Rahdar, A. (2024) · Nanoscale · doi:10.1039/d3nr05656b · Cited by 47
Lardeux, H., Stavenhagen, K., Paris, C., Dueholm, R., Kurek, C., Maria, L. D., Gnerlich, F. A., Leek, T., Czechtizky, W., Guillarme, D., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01384 · Cited by 47
Towards control of cellular decision-making networks in the epithelial-to-mesenchymal transition
Zañudo, J. G. T., Guinn, M. T., Farquhar, K. S., Szenk, M., Steinway, S. N., Balázsi, G., & Albert, R. (2019) · Physical Biology · doi:10.1088/1478-3975/aaffa1 · Cited by 47
Bon, C., Luffarelli, R., Russo, R., Fortuni, S., Pierattini, B., Santulli, C., Fimiani, C., Persichetti, F., Cotella, D., Mallamaci, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz798 · Cited by 48
Nuzzo, S., Roscigno, G., Affinito, A., Ingenito, F., Quintavalle, C., & Condorelli, G. (2019) · Cancers · doi:10.3390/cancers11101521 · Cited by 48
Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer
Levačić, A. K., Berger, S., Müller, J., Wegner, A., Lächelt, U., Dohmen, C., Rudolph, C., & Wagner, E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.016 · Cited by 47
Yu, X., Fang, C., Zhang, K., & Su, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081581 · Cited by 48
Hu, M., Han, Y., Zhang, X., Tian, S., Shang, Z., Yuan, Z., & He, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07077-y · Cited by 58
Liang, X., Sun, H., Nichols, J. G., Allen, N., Wang, S., Vickers, T. A., Shen, W., Hsu, C., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky841 · Cited by 46
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 48
Nanoparticle-Based Combination Therapy for Ovarian Cancer
Wu, Y., Yang, Y., Lv, X., Gao, M., Gong, X., Yao, Q., & Liu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s394383 · Cited by 45
Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA
Zhang, M., Hussain, A., Hu, B., Yang, H., Li, C., Guo, S., Han, X., Li, B., Dai, Y., Cao, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50752-9 · Cited by 45
Garcia, J. P., Stein, J. M., Cai, Y., Riemers, F. M., Wexselblatt, E., Wengel, J., Tryfonidou, M. A., Yayon, A., Howard, K. A., & Creemers, L. B. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.030 · Cited by 45
Chen, J., Yang, H.-H., Yin, W., Zhang, Y., Ma, Y., Chen, D., Xu, Y., Liu, S. M., Zhang, L., Dai, Z., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05920 · Cited by 45
Short Hairpin RNAs for Strand-Specific Small Interfering RNA Production
Sheng, P., Flood, K. A., & Xie, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00940 · Cited by 52
siRNA Therapeutics: Future Promise for Neurodegenerative Diseases
Amiri, A., Barreto, G. E., Sathyapalan, T., & Sahebkar, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210402104054 · Cited by 46
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases
Abdelaal, A. M., & Kasinski, A. L. (2021) · NAR Cancer · doi:10.1093/narcan/zcab030 · Cited by 45
Lipid nanomaterials-based RNA therapy and cancer treatment
Zhang, X., Hai, L., Gao, Y., Yu, G., & Sun, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.004 · Cited by 46
Du, R., Wang, C., Zhu, L., & Yang, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102236 · Cited by 45
Lipid nanoparticle‐mediated RNA delivery for immune cell modulation
Kim, E. H., Teerdhala, S. V., Padilla, M. S., Joseph, R. A., Li, J. J., Haley, R. M., & Mitchell, M. J. (2024) · European Journal of Immunology · doi:10.1002/eji.202451008 · Cited by 48
A battery-free nanofluidic intracellular delivery patch for internal organs
Yin, D., Wang, P., Hao, Y., Yue, W. W., Jiang, X., Yao, K., Wang, Y., Hang, X., Xiao, A., Zhou, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08943-x · Cited by 48
Chemical modulation of siRNA lipophilicity for efficient delivery
Tai, W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.022 · Cited by 45
Li, J., Peng, H., Zhang, W., Li, M., Wang, N., Peng, C., Zhang, X., & Li, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c08756 · Cited by 43
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
Recent Advances of Polycationic siRNA Vectors for Cancer Therapy
Bholakant, R., Qian, H., Zhang, J., Huang, X., Huang, D., Feijén, J., Zhong, Y., & Chen, W. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00438 · Cited by 43
Cheng, Y., Sun, C., Liu, R., Yang, J., Dai, J., Zhai, T., Lou, X., & Xia, F. (2019) · Angewandte Chemie · doi:10.1002/ange.201901527 · Cited by 43
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Synergistic siRNA Loading of Extracellular Vesicles Enables Functional Delivery into Cells
Roerig, J., Mitrach, F., Schmid, M., Hause, G., Hacker, M. C., Wölk, C., & Schulz‐Siegmund, M. (2022) · Small Methods · doi:10.1002/smtd.202201001 · Cited by 44
Functionalized PAMAM constructed nanosystems for biomacromolecule delivery
Wong, K. H., Guo, Z., Law, M. K., & Chen, M. (2022) · Biomaterials Science · doi:10.1039/d2bm01677j · Cited by 43
Antisense oligonucleotide based therapeutics and its applications against bacterial infections
Angrish, N., & Khare, G. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100166 · Cited by 43
Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions
Sharma, A., Vaghasiya, K., Ray, E., & Verma, R. K. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1374390 · Cited by 42
Transcription factors: Time to deliver
Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.004 · Cited by 44
Efficient Cytosolic Delivery Using Crystalline Nanoflowers Assembled from Fluorinated Peptoids
Song, Y., Wang, M., Li, S., Jin, H., Cai, X., Du, D., Li, H., Chen, C., & Lin, Y. (2018) · Small · doi:10.1002/smll.201803544 · Cited by 42
ROS-Sensitive Cross-Linked Polyethylenimine for Red-Light-Activated siRNA Therapy
Wang, J., He, X., Shen, S., Cao, Z., & Yang, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18697 · Cited by 43
Surfactant Protein B Promotes Cytosolic SiRNA Delivery by Adopting a Virus-like Mechanism of Action
Guagliardo, R., Herman, L., Penders, J., Zamborlin, A., Keersmaecker, H. D., de Vyver, T. V., Verstraeten, S. L., Merckx, P., Mingeot‐Leclercq, M., Echaide, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c04489 · Cited by 43
Mahajan, U. M., Li, Q., Alnatsha, A., Maas, J., Orth, M., Maier, S. H., Peterhansl, J., Regel, I., Sendler, M., Wagh, P. R., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.055 · Cited by 46
Biessen, E. A. L., & van Berkel, T. J. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316290 · Cited by 42
Viteri, S., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.01 · Cited by 42
Clinical Pharmacokinetics of Approved RNA Therapeutics
Jo, S. J., Chae, S. U., Lee, C. B., & Bae, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010746 · Cited by 41
Akishiba, M., & Futaki, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00156 · Cited by 41
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
Reid, G., Johnson, T. G., & van Zandwijk, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00105 · Cited by 41
Ly, S., Echeverria, D., Sousa, J., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.029 · Cited by 38
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles
Ageely, E. A., Chilamkurthy, R., Jana, S. K., Abdullahu, L., O’Reilly, D., Jensik, P. J., Damha, M. J., & Gagnon, K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-26989-z · Cited by 40
Yuan, Z., Wang, B., Teng, Y., Ho, W., Hu, B., Boakye‐Yiadom, K. O., Xu, X., & Zhang, X. (2022) · Nanoscale · doi:10.1039/d1nr07880a · Cited by 40
An mRNA vaccine elicits STING-dependent antitumor immune responses
Chen, Z., Meng, C., Mai, J., Liu, Y., Li, H., & Shen, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.013 · Cited by 41
Innovative approaches in transforming microRNAs into therapeutic tools
Samad, A. F. A., & Kamaroddin, M. F. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1768 · Cited by 42
Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking
Mangla, P., Vicentini, Q., & Biscans, A. (2023) · Cells · doi:10.3390/cells12182253 · Cited by 44
Tawiah, K. D., Porciani, D., & Burke, D. H. (2017) · Biomedicines · doi:10.3390/biomedicines5030051 · Cited by 40
Quantitative measurement of cytosolic penetration using the chloroalkane penetration assay
Deprey, K. L., & Kritzer, J. A. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.03.003 · Cited by 39
Gene Therapy Based on Nucleic Acid Nanostructure
Wu, X., Wu, T., Liu, J., & Ding, B. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001046 · Cited by 42
RNA-based therapeutics to treat human fungal infections
Bruch, A., Kelani, A. A., & Blango, M. G. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.007 · Cited by 39
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Protein-based delivery systems for RNA delivery
Zhu, H., Luo, H., Chang, R., Yang, Y., Liu, D., Ji, Y. R., Qin, H., Rong, H., & Yin, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.032 · Cited by 40
Silvestrini, A. V. P., Morais, M. F., Debiasi, B. W., Praça, F. S. G., & Bentley, M. V. L. B. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115198 · Cited by 40
An Endosomal Escape Trojan Horse Platform to Improve Cytosolic Delivery of Nucleic Acids
Narum, S. M., Deal, B. R., Ogasawara, H., Mancuso, J. N., Zhang, J., & Salaita, K. S. (2024) · ACS Nano · doi:10.1021/acsnano.3c09027 · Cited by 41
Wang, C., Wang, S., Xue, Y., Zhong, Y., Li, H., Hou, X., Kang, D. D., Liu, Z., Tian, M., Wang, L., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02487-7 · Cited by 53
Paliouras, A. R., Monteverde, T., & Garofalo, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.029 · Cited by 39
Nucleic Acid-Based Therapeutics for Pulmonary Diseases
Chen, J., Tang, Y., Liu, Y., & Dou, Y. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1183-0 · Cited by 41
Advances in Indocyanine Green-Based Codelivery Nanoplatforms for Combinatorial Therapy
Xu, P., Zheng, X., Kankala, R. K., Wang, S., & Chen, A. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01644 · Cited by 39
Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia
Yun, S., Lee, S., Goh, E.-A., Kwon, O. S., Choi, W., Kim, J., Lee, M. S., Choi, S. J., Lim, S. S., Moon, T. K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05544-w · Cited by 38
Yan, J., Zhang, H., Li, G., Su, J., Wei, Y., & Xu, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.012 · Cited by 40
Minimizing the ratio of ionizable lipid in lipid nanoparticles for in vivo base editing
Chen, Q., Wang, X., Zhang, Y., Tian, M., Duan, J., Zhang, Y., & Yin, H. (2024) · National Science Review · doi:10.1093/nsr/nwae135 · Cited by 41
Exploiting Nanomaterial‐Mediated Autophagy for Cancer Therapy
Wei, W., Rosenkrans, Z. T., Luo, Q., Lan, X., & Cai, W. (2018) · Small Methods · doi:10.1002/smtd.201800365 · Cited by 41
Yang, C., Yang, G. Y., Ouyang, Q., Kuang, S., Song, P., Xu, G., Poenar, D. P., Zhu, G., Yong, K., & Wang, Z. L. (2019) · Nano Energy · doi:10.1016/j.nanoen.2019.103901 · Cited by 38
Nanoparticle-siRNA: A Potential Strategy for Ovarian Cancer Therapy?
Aghamiri, S., Fallah-Mehrjardi, K., Shabani, S., Keshavarz‐Fathi, M., Kargar, S., & Rezaei, N. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0379 · Cited by 38
Chen, Y., Zhao, R., Li, L., & Zhao, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202206485 · Cited by 38
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 44
Guo, X., Guo, M., Cai, R., Hu, M., Rao, L., Su, W., Liu, H., Gao, F., Zhang, X., Liu, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp3680 · Cited by 37
Juliano, R. L., Wang, L., Tavares, F. X., Brown, E., James, L. I., Ariyarathna, Y., Ming, X., Mao, C., & Suto, M. J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1320 · Cited by 37
Harnessing pH-Sensitive Polycation Vehicles for the Efficient siRNA Delivery
Wang, C., Wang, X., Du, L., Dong, Y., Hu, B., Zhou, J., Shi, Y., Bai, S., Huang, Y., Cao, H., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c17866 · Cited by 37
Dendrimers as Drug Nanocarriers: The Future of Gene Therapy and Targeted Therapies in Cancer
Pietryga, I. F., Ziemba, B., Messmer, B. T., & Skowronska‐Krawczyk, D. (2018) · InTech eBooks · doi:10.5772/intechopen.75774 · Cited by 39
Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain
Kim, T., Viard, M., Afonin, K. A., Gupta, K., Popov, M., Salotti, J., Johnson, P. F., Linder, C., Heldman, E., & Shapiro, B. A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.02.011 · Cited by 36
Long Noncoding RNAs as Therapeutic Targets
Pierce, J. B., Zhou, H., Simion, V., & Feinberg, M. W. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-92034-0_9 · Cited by 40
Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 36
Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.19430 · Cited by 37
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 35
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
MicroRNA antagonist therapy during normothermic machine perfusion of donor kidneys
Thompson, E. R., Sewpaul, A., Figuereido, R., Bates, L., Tingle, S. J., Ferdinand, J. R., Situmorang, G. R., Ladak, S. S., Connelly, C., Hosgood, S. A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16929 · Cited by 35
LncRNAs and CircRNAs in cancer
Yin, X., Lin, H., Lin, L., Miao, L., He, J., & Zhuo, Z. (2022) · MedComm · doi:10.1002/mco2.141 · Cited by 38
Structure‐Property Relationships Governing Membrane‐Penetrating Behaviour of Complex Coacervates
Lu, T., Hu, X., van Haren, M. H. I., Spruijt, E., & Huck, W. T. S. (2023) · Small · doi:10.1002/smll.202303138 · Cited by 32
Costabile, G., Conte, G., Brusco, S., Savadi, P., Miro, A., Quaglia, F., d’Angelo, I., & Ungaro, F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030347 · Cited by 37
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 38
Zang, Y., Zhang, X., Yan, L., Gu, G., Li, D., Zhang, Y., Fang, L., Fu, S., Ren, J., & Xu, Z. (2017) · Journal of Cancer · doi:10.7150/jca.19594 · Cited by 34
Zhang, H., Liu, A., Feng, X., Tian, L., Bo, W., Wang, H., & Hu, Y. (2017) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2017.09.019 · Cited by 34
Noncovalent tagging of siRNA with steroids for transmembrane delivery
Tai, W., & Gao, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.007 · Cited by 34
Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route
Xin, X., Teng, C., Du, X., Lv, Y., Xiao, Q., Wu, Y., He, W., & Yin, L. (2018) · Theranostics · doi:10.7150/thno.23804 · Cited by 34
Juliano, R. L. (2021) · Biomedicines · doi:10.3390/biomedicines9050512 · Cited by 34
microRNAs, the Link Between Dengue Virus and the Host Genome
Su, Y., Lin, T. H., Liu, C., Cheng, C., Han, X., & Jiang, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.714409 · Cited by 34
Aggregation‐Induced Emission Materials that Aid in Pharmaceutical Research
Wang, B., Liu, S., Liu, X., Hu, R., Qin, A., & Tang, B. Z. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101067 · Cited by 34
New RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics
Riscado, M., Baptista, B., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091397 · Cited by 34
Yuan, P., Yang, F., Liew, S. S., Yan, J., Dong, X., Wang, J., Du, S., Mao, X., Gao, L., & Yao, S. Q. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121376 · Cited by 34
Serres‐Bérard, T. D., Benichou, S. A., Jauvin, D., Boutjdir, M., Puymirat, J., & Chahine, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113359 · Cited by 38
Humphreys, S. C., Thayer, M. B., Campbell, J., Chen, W. L. K., Adams, D. J., Lade, J. M., & Rock, B. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01839 · Cited by 34
Laisney, J., Gurusamy, D., Baddar, Z. E., Palli, S. R., & Unrine, J. M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06234 · Cited by 36
Environment‐Responsive Lipid/siRNA Nanoparticles for Cancer Therapy
Lu, Z., Laney, V. E. A., Hall, R. C. W., & Ayat, N. R. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001294 · Cited by 33
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
